About us

Our Mission

i3 was created in collaboration with the Massachusetts General Hospital/Harvard Medical School (MGH) and the Technical University of Munich (TUM) to commercialize novel Cardiovascular Imaging Technologies.

World-Class Research & Leadership

i3's founders are dedicated to the advancement of Biological Imaging Modalities relating to the early detection of Coronary Artery Disease and post-interventional therapeutic viability.

Motivation

Coronary artery disease (CAD) is the #1 cause of death world-wide. Stents are widely used to treat CAD accounting for 2 million percutaneous interventions (PCIs)/Year.

However, target lesions are missed in 30% of PCIs which causes worse long-term clinical outcomes for patients (Read more). In addition, despite significant improvements in Drug-eluting stent technology, 10% PCIs over the past decade were performed to treat in-stent restenosis (ISR) in the US. PCIs for ISR are associated with a higher risk for major cardiovascular events than PCIs performed for de novo lesions (Read more).

i3 believes that, with its novel imaging technologies many of those failed procedures could potentially be avoided which has the potential to save millions in healthcare cost and improve clinical patient outcomes.

i3 Leadership

R. Scott Jones - Chairman & CEO

Farouc A. Jaffer, MD, PhD - Co-Founder

Mr. Jones is a seasoned executive with a successful leadership track-record across various healthcare and medical device sectors. His experience in the cardiovascular imaging industry includes leadership of the GE Medical Systems Cardiovascular Business for the Americas as well as GE Asia. He has led and conducted successful exits in businesses from start-ups to those as large as 7,000 employees.

Farouc A. Jaffer, MD, PhD - Co-Founder

Dr. Jaffer is a widely acclaimed interventional cardiologist and researcher in the field of biological imaging. He is an associate professor of medicine and Director of Coronary Intervention at the Massachusetts General Hospital/Harvard Medical School and speaks frequently at scientific sessions throughout the world. He is a Fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiac Angiography and Interventions. Dr. Jaffer's main area of research interest is in developing translational molecular imaging approaches to investigate inflammation in vascular biology from mouse to patients.

Vasilis Ntziachristos, PhD - Co-Founder

Philipp Rauschendorfer, PhD - Chief Scientific Officer

Dr. Ntziachristos is a widely acclaimed researcher and pioneer in the field of biological imaging. He is Professor of Medicine and Electrical Engineering at the Technical University of Munich and Chair for Biological Imaging (CBI). In addition he is the Director of the Institute for Biological and Medical Imaging (IBMI) at the Helmholtz Zentrum Munchen and Director of Bioengineering at the Helmholtz Pioneering Campus. Professor Ntziachristos is the editor of the Journal of Photoacoustics, has authored hundreds of peer-reviewed publications on optical and optoacoustic imaging and has received numerous awards and distinctions, including the Gold Medal from the Society for Molecular Imaging (2015), the Gottfried Leibnitz prize (2013), which is the top scientific distinction in Germany, the Erwin Schrödinger Award (2012) and was named one of the world’s top innovators by the Massachusetts Institute of Technology (MIT) Technology Review in 2004.

Philipp Rauschendorfer, PhD - Chief Scientific Officer

Dr. Rauschendorfer is a well-rounded Engineer with a deep knowledge base in medical imaging. His successful research at the Technical University of Munich and Massachusetts General Hospital/Harvard Medical School have established him as a seasoned scientist. Dr. Rauschendorfer is an expert in the field of intravascular imaging and will apply his innovative skills, and natural leadership to the growth and expansion of Intravascular Imaging Inc.